A capsule article (100) includes a polymeric body (110) extending along a longitudinal axis from a first end to a second end and defining a capsule cavity (105) containing powder, and a metal foil (120) and a sealant layer (130) covering an outer surface of the polymeric body. A method of forming a hermetic capsule includes the steps of wrapping a capsule, with a metal foil; and enclosing the capsule with a sealant layer to form a hermetic barrier enclosing the capsule.

Device for dispensing a pulverulent product comprising a reservoir unit (100) connected on the one hand, to an air expulsion system (200) and on the other hand to a dispensing head (300) provided with a dispensing orifice (310), said reservoir unit (100) comprising a reservoir (110) having substantially the form of a hollow cylinder, with a distal opening (111), a proximal opening (112), and a metering passage (113) connecting said distal and proximal openings (111, 112), a one-way valve (115) being positioned between said metering passage (113) and said distal opening (111), said proximal opening (112) of said reservoir (110) forming a filling cone which tapers towards said metering passage (113) to facilitate filling of said metering passage (113) with a dose of powder.

Device for dispensing a pulverulent product comprising a reservoir unit (100) connected on the one hand, to an air expulsion system (200) and on the other hand to a dispensing head (300) provided with a dispensing orifice (310), said reservoir unit (100) comprising a reservoir (110) having substantially the form of a hollow cylinder, with a distal opening (111), a proximal opening (112), and a metering passage (113) connecting said distal and proximal openings (111, 112), a one-way valve (115) being positioned between said metering passage (113) and said distal opening (111), said proximal opening (112) of said reservoir (110) forming a filling cone which tapers towards said metering passage (113) to facilitate filling of said metering passage (113) with a dose of powder.

The present invention relates to a device for delivering acetylsalicylic acid or a salt thereof for the administration thereof through oral inhalation route for the preventive or curative treatment of thrombohemolytic events, in particular for myocardial infarction.

The present invention an electronic inhaler for the delivery of pharmaceuticals through vaporization.

A dry-powder inhaler may include a first casing portion, a second casing portion, and a hinge arrangement connecting the first casing portion and the second casing portion. The dry-powder inhaler may be assembled by folding the first casing portion and the second casing portion together. The first casing portion may include a cavity for receiving a dose blister foil, said cavity being adapted to contain a dry-powder medicament. The first casing portion and the second casing portion when folded together may be adapted to form an inlet for allowing a lidding foil extending out there from and an outlet for providing the medicament.

A sublingual type medication delivery device includes a container body having a predetermined volume of solvent with a spray dispenser attached at one end of the container and at the opposite end of the container is a housing which contains medication to be discharged into the container and mixed with the solvent to form a diluted medication for fractional delivery of the medication over a period of time. The housing can either be a tablet crusher for introducing medicament in solid form into the container or the housing can be a capsule having liquid medicament that is delivered through a needle that pierces the capsule wall.

A system may include an external device and an inhaler. The external device may include a processor, a communication circuit, and memory. The inhaler may include a mouthpiece, medicament, a mechanical dose counter, and an electronics module comprising a processor and a communication circuit. The electronics module may record a dosing event when the inhaler is actuated, such as when the mouthpiece cover is opened, and send a signal indicating the dosing event to the external device. The external device may receive a mechanical dose reading of the mechanical dose counter, determine an electronic dose reading based on the signal indicating the dosing event, determine that a discrepancy between the mechanical dose reading and the electronic dose reading exceeds a threshold, and notify the user of the discrepancy, for example, by providing a notification to the user by way of a mobile application residing on the external device.

Described herein are an interactive apparatus and methods for sensing and measuring real-time characteristic patterns of a subject's use of a dry powder inhalation system. The inhaler device can be used in a wireless communication mode to communicate with a display to assess the subject's usage of the inhalation system concurrently as the inhalation is performed and thus the subject's inhalation can be evaluated as well as the performance of the inhalation system. The system can also detect the identity of the medicament, its dosage, lot, expiration, etc. and the characteristics profile of a dry powder formulation emitted from the inhalation system in use.

In alternative embodiments, provided are pharmaceutical compositions comprising combinations of drugs, including products of manufacture and kits, and methods for using them, for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a coronavirus infection, or a COVID-19 or a 2019-nCoV (or so-called Wuhan coronavirus) infection, or an infection caused by a virus in the subfamily Orthocoronavirinae, or a virus in the family Coronaviridae, or a virus in the order Nidovirales. In alternative embodiments, combinations, or cocktails, of a drug or drugs as provided herein are administered either enterally, parenterally and/or by inhalation. In alternative embodiments, combinations, or cocktails, of drugs as provided herein are used to block intracellular metabolic pathways and prevent progression of the infection to clinical illness and death. In alternative embodiments, novel aerosol, spray or mist or powder formulations for inhalation are provided. In alternative embodiments, provided are therapeutic combinations of drugs or a drug, a pharmaceutical dosage form, a drug delivery device, or a product of manufacture, comprising: opaganib or YELIVA™, or opaganib or YELIVA™ and oral and/or inhaled chloroquine (or ARALEN™) chloroquine phosphate, chloroquine diphosphate and/or hydroxychloroquine (optionally, PLAQUENIL™), with or without azithromycin, wherein optionally each or all of the opaganib, the chloroquine (or ARALEN™), chloroquine phosphate, chloroquine diphosphate and/or hydroxychloroquine (optionally, PLAQUENIL™), and/or azithromycin, and others, are in or formulated as a formulation for inhalation, for example, formulated as an aerosol, spray, mist, liquid or powder.